These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 1159052

  • 1. Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease.
    Pimstone BL, Le Roith D, Epstein S, Kronheim S.
    J Clin Endocrinol Metab; 1975 Aug; 41(2):392-3. PubMed ID: 1159052
    [Abstract] [Full Text] [Related]

  • 2. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man.
    Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M.
    J Clin Endocrinol Metab; 1979 Jan; 48(1):50-3. PubMed ID: 422706
    [Abstract] [Full Text] [Related]

  • 3. Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure.
    Pimstone B, Epstein S, Hamilton SM, LeRoith D, Hendricks S.
    J Clin Endocrinol Metab; 1977 Feb; 44(2):356-60. PubMed ID: 320223
    [Abstract] [Full Text] [Related]

  • 4. Marked prolongation in disappearance half-time of plasma cholecystokinin-octapeptide in patients with hepatic cirrhosis.
    Kanayama S, Himeno S, Kurokawa M, Shinomura Y, Kuroshima T, Okuno M, Tsuji K, Higashimoto Y, Ikei N, Hashimura E.
    Am J Gastroenterol; 1985 Jul; 80(7):557-60. PubMed ID: 4014106
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin and serum gastrin in normal subjects and in patients with pernicious anaemia, chronic liver and renal disease.
    Le Roith D, Vinik AI, Epstein S, Baron P, Olkenitzky MN, Pimstone BL.
    S Afr Med J; 1975 Sep 13; 49(39):1601-4. PubMed ID: 1179234
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The half-life of exogenous growth hormone after suppression of endogenous growth hormone secretion with somatostatin.
    Hindmarsh PC, Matthews DR, Brain CE, Pringle PJ, di Silvio L, Kurtz AB, Brook CG.
    Clin Endocrinol (Oxf); 1989 Apr 13; 30(4):443-50. PubMed ID: 2574646
    [Abstract] [Full Text] [Related]

  • 9. Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects on both hepatic and extrahepatic tissues in man.
    MacGorman LR, Rizza RA, Gerich JE.
    J Clin Endocrinol Metab; 1981 Sep 13; 53(3):556-9. PubMed ID: 6114964
    [Abstract] [Full Text] [Related]

  • 10. Thyrotropin-releasing hormone (TRH)-induced growth hormone (hGH) responses in cirrhotic men.
    Van Thiel DH, Gavaler JS, Wight C, Smith WI, Abuid J.
    Gastroenterology; 1978 Jul 13; 75(1):66-70. PubMed ID: 122603
    [Abstract] [Full Text] [Related]

  • 11. Plasma clearance of intravenously administered pituitary human growth hormone: gel filtration studies of heterogeneous components.
    Hendricks CM, Eastman RC, Takeda S, Asakawa K, Gorden P.
    J Clin Endocrinol Metab; 1985 May 13; 60(5):864-7. PubMed ID: 3980671
    [Abstract] [Full Text] [Related]

  • 12. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
    Rizza RA, Cryer PE, Gerich JE.
    J Clin Invest; 1979 Jul 13; 64(1):62-71. PubMed ID: 36413
    [Abstract] [Full Text] [Related]

  • 13. Metabolic clearance and production rates of human growth hormone.
    Taylor AL, Finster JL, Mintz DH.
    J Clin Invest; 1969 Dec 13; 48(12):2349-58. PubMed ID: 5355346
    [Abstract] [Full Text] [Related]

  • 14. Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects.
    Sohmiya M, Kato Y.
    J Clin Endocrinol Metab; 1992 Dec 13; 75(6):1487-90. PubMed ID: 1464653
    [Abstract] [Full Text] [Related]

  • 15. [Determination of growth hormone in plasma of psoriatic arthritis, psoriasis vulgaris and seronegative spondylarthritis].
    Partsch G, Schwarzer C, Dunky A, Mayer F, Gschnait F, Neumüller J, Eberl R.
    Z Rheumatol; 1985 Dec 13; 44(6):267-9. PubMed ID: 2869626
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Growth hormone (GH) binding protein and GH interactions in vivo in the guinea pig.
    Fairhall KM, Carmignac DF, Robinson IC.
    Endocrinology; 1992 Oct 13; 131(4):1963-9. PubMed ID: 1396340
    [Abstract] [Full Text] [Related]

  • 18. Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin.
    Faria AC, Veldhuis JD, Thorner MO, Vance ML.
    J Clin Endocrinol Metab; 1989 Mar 13; 68(3):535-41. PubMed ID: 2563734
    [Abstract] [Full Text] [Related]

  • 19. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
    Haffner D, Schaefer F, Girard J, Ritz E, Mehls O.
    J Clin Invest; 1994 Mar 13; 93(3):1163-71. PubMed ID: 8132756
    [Abstract] [Full Text] [Related]

  • 20. Long-term bromocriptine treatment and somatostatin in acromegaly.
    Gáspár L, László FA.
    Endokrinologie; 1980 Oct 13; 76(2):152-62. PubMed ID: 6108852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.